Nebivolol contraindications: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Nebivolol}} {{CMG}}; {{AE}} {{SS}} ==== BYSTOLIC is contraindicated in the following conditions: *Severe bradycardia *Heart block greater than first degree *...") |
No edit summary |
||
Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{SS}} | {{CMG}}; {{AE}} {{SS}} | ||
==== | ==Contraindications== | ||
BYSTOLIC is contraindicated in the following conditions: | BYSTOLIC is contraindicated in the following conditions: | ||
Line 13: | Line 13: | ||
*Patients with severe hepatic impairment (Child-Pugh >B) | *Patients with severe hepatic impairment (Child-Pugh >B) | ||
*Patients who are hypersensitive to any component of this product.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = BYSTOLIC (NEBIVOLOL HYDROCHLORIDE) TABLET [FOREST LABORATORIES, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8b8ad213-1dc8-454e-a524-075685c0e1a8 | publisher = | date = | accessdate = 4 February 2014 }}</ref> | *Patients who are hypersensitive to any component of this product.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = BYSTOLIC (NEBIVOLOL HYDROCHLORIDE) TABLET [FOREST LABORATORIES, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8b8ad213-1dc8-454e-a524-075685c0e1a8 | publisher = | date = | accessdate = 4 February 2014 }}</ref> | ||
Revision as of 19:41, 4 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Contraindications
BYSTOLIC is contraindicated in the following conditions:
- Severe bradycardia
- Heart block greater than first degree
- Patients with cardiogenic shock
- Decompensated cardiac failure
- Sick sinus syndrome (unless a permanent pacemaker is in place)
- Patients with severe hepatic impairment (Child-Pugh >B)
- Patients who are hypersensitive to any component of this product.[1]
References
- ↑ "BYSTOLIC (NEBIVOLOL HYDROCHLORIDE) TABLET [FOREST LABORATORIES, INC.]". Retrieved 4 February 2014.